Inside Australia’s Complex Drug Approval System & What Pharma Companies Must Know |Ep 294| DevReady

In this episode of the DevReady Podcast, Anthony Sapountzis, CTO and Co-Founder of Aerion Technologies and DevReady.Ai speaks with Dr. Diana Lau, Founder and Medical Director of PharmaVerse, about the evolving pharmaceutical industry, healthcare innovation, and the challenges of bringing medicines to market in Australia. Drawing on more than 14 years of experience in medical affairs and pharmaceutical strategy, Dr. Diana shares insights into Australia’s healthcare system, drug approvals, regulatory pathways, and the growing role of artificial intelligence in healthcare. The discussion explores how pharmaceutical companies navigate commercialisation, reimbursement, patient access, and clinician engagement within one of the world’s most highly regulated healthcare markets. Dr. Diana also reflects on her transition from pharmaceutical leadership into entrepreneurship and her mission to help global healthcare innovations reach Australian patients faster.
Dr. Diana explains how her background in academic medical research led her into the pharmaceutical industry, where she discovered a passion for translating scientific discoveries into real-world patient outcomes. She discusses her time as Country Medical Director at Teva Pharmaceuticals Australia, where she led medical affairs teams responsible for scientific engagement, clinician relationships, and strategic product support. The conversation highlights the complexity of the pharmaceutical sector, from clinical trials and regulatory approvals through to market access, reimbursement, and patient safety. Dr. Diana also outlines why Australia presents both opportunities and challenges for pharmaceutical companies due to its strict regulatory standards, healthcare infrastructure, and government-funded Pharmaceutical Benefits Scheme (PBS).
Anthony and Dr. Diana then explore how medicines are evaluated for cost effectiveness in Australia and why clinical data, pricing models, and patient outcomes all play a critical role in securing government reimbursement. Diana shares insights into how pharmaceutical companies must tailor their strategies for the Australian market, including understanding local healthcare systems, clinician behaviours, and patient journeys. The discussion also covers how pharmaceutical marketing differs from traditional consumer marketing, with strict regulations preventing direct advertising of prescription medicines to the public. Instead, pharmaceutical communication focuses on clinician education, scientific evidence, compliance, and peer-to-peer engagement to support informed medical decision-making.
The episode also dives into entrepreneurship and the realities of building a specialised consulting business within the healthcare sector. Diana explains how PharmaVerse provides embedded, fractional expertise that allows pharmaceutical companies to access local strategic guidance without immediately establishing a full Australian operation. Anthony and Dr. Diana discuss the…